Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,258.7
19.8 (0.61%)

 

  • STI Straits Times Index
    3,258.7
    19.8 (0.61%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,604.4
    9.6 (0.60%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,681.1
    354.4 (1.35%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,909.2
    17.9 (0.62%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,416.8
    113.4 (0.49%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,122.6
    -5.7 (-0.09%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,160.7
    -1.5 (-0.07%)
    Index delayed 20 minutes
  • XAO XAO
    6,871.7
    -27.2 (-0.39%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,209.0M
  • Value: 1,052.2M
  • Rise: 198
  • Fall: 118
  • Unch: 513

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
JCG Investment0.002-
Tritech0.043+0.011
YZJ Shipbldg SGD1.080+0.080
SinoCloud0.001-
AusGroup^0.033+0.003
Rex Intl0.196+0.005
Golden Agri-Res0.255-
SingTel3.220+0.040
Yoma Strategic0.400+0.015
TEE Intl0.048+0.002

World Indices

World Indices
Name Last Change
Nasdaq 8,540.8 +61.8
HSI 26,681.1 +354.4
HSCEI 10,556.6 +131.8
Jakarta 6,122.6 -5.7
Nikkei 225 23,416.8 +113.4
SSE Comp 2,909.2 +17.9
Shanghai A 3,048.0 +18.8
Shanghai B 254.9 -0.4
PSE Comp 0.0
KOSPI 2,160.7 -1.5

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

ACTINIUM PHARMACEUTICALS INC ACTINIUM PHARMACEUTICALS
Updated on 15 Nov 2019 (End of trading day)
Last (USD): 0.248 Change: -0.002 High: 0.258 Remarks: -
Change (%): -0.76 Low: 0.240
Open 0.250 Yesterday's Close 0.25
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 594,853 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.29560 Trailing EPS (USD) e -0.29514 NAV (USD) b 0.1242
PE a - Trailing PE f - Price / NAV b 1.9976
Dividend (USD) d - Cash In Hand (USD) g 0.1795 Issued & Paid-up Shares c 164,701,000
Dividend Yield (%) d - Price / Cash In Hand g 1.382 Treasury Shares h -
Beta - 75 Daysi 0.971 R-Squared - 75 Days(%)i 4.21 Market Cap (M) 19.853
Beta - 500 Daysi 0.874 R-Squared - 500 Days (%)i 2.08 Enterprise Value (M) 6.743
Piotroski F Score 0 Exchange Code ATNM Par Value ( $ ) n.a.
52 Weeks Volatility (%) 106.44 Free Float (%) 93.2
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 13 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ACTINIUM PHARMACEUTICALS INC NYSE American 19.853 - - 1.9976 -
Industry Biotechnology NYSE American 68.582 - - 2.6110 -
Local Peer PFENEX INC NYSE American 207.526 - - 3.7168 -
Local Peer 22ND CENTURY GROUP INC NYSE American 146.947 - - 2.6570 -
Local Peer NANOVIRICIDES INC NYSE American 135.605 - - 12.7976 -
Local Peer LINEAGE CELL THERAPEUTICS INC NYSE American 130.321 - - 1.1124 -
Local Peer PALATIN TECHNOLOGIES INC NYSE American 120.912 3.380 3.272 1.2578 -
Local Peer NAVIDEA BIOPHARMACEUTICALS INC NYSE American 111.615 - - -146.4043 -
Local Peer MATINAS BIOPHARMA HOLDINGS INC NYSE American 95.651 - - 2.8169 -
Local Peer CEL-SCI CORP NYSE American 69.366 - - 60.5049 -
Local Peer SYNTHETIC BIOLOGICS INC NYSE American 52.928 - - 515.8750 -
Local Peer ARMATA PHARMACEUTICALS INC NYSE American 41.375 - - 2.2819 -
Local Peer ORAGENICS INC NYSE American 23.937 - - 1.3365 -
Local Peer INDIA GLOBALIZATION CAPITAL INC NYSE American 23.663 - - 0.7574 -
Other Local Peers ISORAY INC (NYSE American), IBIO INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American)
Global Peer AMGEN INC NASDAQ 131,231.478 15.634 16.268 12.0099 2.533
Global Peer CSL ASX 123,447.557 46.012 46.012 16.4967 0.976
Global Peer GILEAD SCIENCES INC NASDAQ 82,323.311 15.091 30.569 3.9955 3.551
Global Peer CELGENE CORP NASDAQ 78,302.774 19.353 13.317 6.4783 -
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer VERTEX PHARMACEUTICAL NASDAQ 53,950.070 25.735 25.166 10.2696 -
Global Peer BIOGEN INC NASDAQ 50,933.363 11.496 9.440 3.6392 -
Global Peer ILLUMINA INC NASDAQ 44,979.795 54.455 46.228 10.1329 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 37,865.336 15.491 17.659 3.6047 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 24,218.966 76.642 22.592 5.1020 0.783
Other Global Peers ALEXION PHARMACEUTICAL INC (NASDAQ), SEATTLE GENETICS INC (NASDAQ), INCYTE CORPORATION (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), BIOMARIN PHARMACEUTICAL (NASDAQ), BEIGENE (HKEx), EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), MODERNA INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), REPLIGEN CORP (NASDAQ), Lonza (SGX), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), GENSCRIPT BIO (HKEx), SPARK THERAPEUTICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), 3SBIO (HKEx), MIRATI THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), IMMUNOMEDICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ALKERMES PLC (NASDAQ), FIBROGEN INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), NATERA INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), HALOZYME THERAPEUTICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), ACCELERON PHARMA (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), XENCOR INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), INSMED INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), HAOHAI BIOTEC (HKEx), AIMMUNE THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), VIELA BIO INC (NASDAQ), EPIZYME INC (NASDAQ), REGENXBIO INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), FRONTAGE (HKEx), VERACYTE INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), FATE THERAPEUTICS (NASDAQ), RADIUS HEALTH INC (NASDAQ), CKLIFE SCIENCES (HKEx), ESPERION THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), POLYNOVO LIMITED (ASX), OPKO HEALTH INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), VIVA BIOTECH (HKEx), INTREXON CORP (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), ASCENTAGE-B (HKEx), SPECTRUM PHARMACEUTICALS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), NEXTCURE INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD (ASX), ROCKET PHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), OMEROS CORP (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), INTELLIA THERAPEUTICS INC (NASDAQ), ASCLETIS-B (HKEx), CORTEXYME INC (NASDAQ), SINOMAB BIO-B (HKEx), PRECISION BIOSCIENCES INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), TRANSLATE BIO INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), RETROPHIN INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), MEIRAGTX HOLDINGS PLC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), CHEMOCENTRYX INC (NASDAQ), XBIOTECH INC (NASDAQ), AGENUS INC (NASDAQ), KADMON HLDGS INC (NYSE), INTRA-CELLUAR THERAPIES INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), SYNTHORX INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), CYTOKINETICS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), ESSEX BIO-TECH (HKEx), MORPHIC HOLDING INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), MERUS B V (NASDAQ), MACROGENICS INC (NASDAQ), AVROBIO INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), DERMIRA INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), RECRO PHARMA INC (NASDAQ), ARDELYX INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), COMPUGEN (NASDAQ), MEDICINOVA INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), LEE'S PHARM (HKEx), TELIX PHARMACEUTIC (ASX), CASI PHARMACEUTICALS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), PERSONALIS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), ANAPTYSBIO INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), NEXT SCIENCE LTD (ASX), EIGER BIOPHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), GERON CORP (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), MANNKIND CORPORATION (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), KAMADA (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), DPHARMA (Bursa), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), XOMA CORP (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ATHERSYS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), CHIASMA INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), CUE BIOPHARMA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), AFFIMED N V (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), JOUNCE THERAPEUTICS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), BICYCLE THERAPEUTICS LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), BBI LIFE SCI (HKEx), NABRIVA THERAPEUTICS PLC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), ENZO BIOCHEM INC (NYSE), UNI-BIO GROUP (HKEx), APTOSE BIOSCIENCES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), IVERIC BIO INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), FIVE PRIME THERAPEUTICS (NASDAQ), IMV INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SESEN BIO INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), CHIMERIX INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), IMUGENE LIMITED (ASX), NOVAVAX INC (NASDAQ), NANTKWEST INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), VBI VACCINES INC CDA (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), PHYLOGICA LIMITED (ASX), AVEO PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), ADURO BIOTECH INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), COHBAR INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), VERMILLION INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), ARAVIVE INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), OTONOMY INC (NASDAQ), VACCINEX INC (NASDAQ), IMMUTEP LTD (ASX), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), SYNLOGIC INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), VERASTEM INC (NASDAQ), TREVENA INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), EQUILLIUM INC (NASDAQ), INFLARX N V (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), ORTHOCELL LIMITED (ASX), INFINITY PHARMACEUTICALS INC (NASDAQ), ORGENESIS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CURIS INC (NASDAQ), CT ENTERPRISE (HKEx), INMUNE BIO INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), PORT (SET), BELLICUM PHARMACEUTICALS (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 2 ORD SHS (NASDAQ), RESTORBIO INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), BIONOMICS LTD (ASX), CELLDEX THERAPEUTICS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), NOVITA HEALTHCARE LTD (ASX), ACTINOGEN MEDICAL LTD (ASX), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), REGENT PACIFIC (HKEx), BIO-PATH HOLDINGS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), SAVARA INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), ZAFGEN INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), BIOTRON (ASX), BIONANO GENOMICS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), BIOSINO BIO-TEC (HKEx), BIOCARDIA INC (NASDAQ), MEMPHASYS LTD (ASX), ONCOLYTICS BIOTECH INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), RHINOMED LIMITED (ASX), ALIMERA SCIENCES INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), EXTRAWELL PHAR (HKEx), MICROBOT MEDICAL INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), AETERNA ZENTARIS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), SOLIGENIX INC (NASDAQ), SENESTECH INC (NASDAQ), ANTEOTECH LIMITED (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), IMMURON LIMITED (ASX), AEVI GENOMIC MEDIC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), VAXART INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), SOPHIRIS BIO INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), CELLMID LIMITED (ASX), ATYR PHARMA INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), TOCAGEN INC (NASDAQ), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), BIOCEPT INC (NASDAQ), Suntar Eco-City^ (SGX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), ADALTA LTD (ASX), PRECIPIO INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), REGENEUS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), HOLISTA COLLTECH LIMITED (ASX), TROVAGENE INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), CONATUS PHARMACEUTICALS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 20 ORD SHS (NASDAQ), ADVAXIS INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), MEGASUN (Bursa), CCP TECHNOLOGIES LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), OCUGEN INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), HAO WEN HLDGS (HKEx), BIOXYNE LIMITED (ASX), TRILLIUM THERAPEUTICS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), MGRC (Bursa), ANATARA LIFESCIENCES LTD (ASX), ACHIEVE LIFE SCIENCE INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), TBG DIAGNOSTICS LTD (ASX), QT Vascular (SGX), MEDIBIO LIMITED (ASX), XENETIC BIOSCIENCES INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), NANOLLOSE LTD (ASX), SENECA BIOPHARMA INC (NASDAQ), SPHERIX INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), BPH ENERGY LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), FACTOR THERAPEUTICS LIMITED (ASX), PLUS THERAPEUTICS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), OPGEN INC (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.002
-0.76 %
10 Days --0.033
-11.71 %
20 Days -+0.037
+17.58 %
Medium Term Return 3 Months -+0.046
+22.82 %
6 Months --0.057
-18.66 %
1 Year --0.178
-41.76 %
Long Term Return 2 Years --0.425
-63.14 %
3 Years --0.782
-75.91 %
5 Years --5.742
-95.86 %
Annualised Return Annualised --
-47.10 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.190 - 0.709 Change From 1 Year Low +0.058 % Change From 1 Year Low (%) +30.58
Change From 1 Year High -0.460 % Change From 1 Year High (%) -64.98
2 Years Range 0.190 - 0.865 Change From 2 Years Low +0.058 % Change From 2 Years Low (%) +30.58
Change From 2 Years High -0.617 % Change From 2 Years High (%) -71.32
5 Years Range 0.190 - 6.600 Change From 5 Years Low +0.058 % Change From 5 Years Low (%) +30.58
Change From 5 Years High -6.352 % Change From 5 Years High (%) -96.24
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.

Historical Price Data

Date Open High Low Close Volume VWAP
15 Nov 2019 0.250 0.258 0.240 0.248 594,853 -
14 Nov 2019 0.244 0.258 0.243 0.250 290,190 -
13 Nov 2019 0.265 0.265 0.248 0.248 821,522 -
12 Nov 2019 0.250 0.267 0.250 0.260 618,167 -
11 Nov 2019 0.259 0.270 0.248 0.250 1,166,903 -
08 Nov 2019 0.270 0.270 0.258 0.258 703,638 -
07 Nov 2019 0.270 0.280 0.263 0.270 518,154 -
06 Nov 2019 0.270 0.286 0.263 0.271 921,578 -
05 Nov 2019 0.300 0.300 0.257 0.265 1,464,456 -
04 Nov 2019 0.275 0.290 0.268 0.281 2,453,050 -
01 Nov 2019 0.254 0.290 0.249 0.262 2,781,550 -
31 Oct 2019 0.268 0.268 0.240 0.249 2,152,426 -
30 Oct 2019 0.230 0.245 0.225 0.237 1,741,499 -
29 Oct 2019 0.230 0.244 0.218 0.238 4,210,480 -
28 Oct 2019 0.300 0.320 0.233 0.249 14,640,940 -
25 Oct 2019 0.410 0.410 0.324 0.352 13,634,090 -
24 Oct 2019 0.220 0.350 0.220 0.309 20,903,610 -
23 Oct 2019 0.220 0.223 0.206 0.217 301,475 -
22 Oct 2019 0.210 0.215 0.200 0.210 216,117 -
21 Oct 2019 0.225 0.225 0.200 0.211 343,541 -
18 Oct 2019 0.199 0.215 0.199 0.212 482,293 -
17 Oct 2019 0.210 0.215 0.200 0.200 404,061 -
Summary
Current 2 Weeks
(04 Nov 2019 to 15 Nov 2019)
0.275 0.300 0.240 0.248 9,552,511 -
Previous 2 Weeks
(21 Oct 2019 to 01 Nov 2019)
0.225 0.300 0.200 0.262 60,925,728 -
4 Weeks from
(23 Sep 2019 to 18 Oct 2019)
0.211 0.300 0.211 0.212 8,050,385 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.